CLPT vs. DCTH, DRTS, QIPT, ARAY, CVRX, OBIO, PROF, TELA, KRMD, and BWAY
Should you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include Delcath Systems (DCTH), Alpha Tau Medical (DRTS), Quipt Home Medical (QIPT), Accuray (ARAY), CVRx (CVRX), Orchestra BioMed (OBIO), Profound Medical (PROF), TELA Bio (TELA), KORU Medical Systems (KRMD), and BrainsWay (BWAY). These companies are all part of the "surgical & medical instruments" industry.
Delcath Systems (NASDAQ:DCTH) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
ClearPoint Neuro has a net margin of -78.84% compared to ClearPoint Neuro's net margin of -1,080.72%. Delcath Systems' return on equity of -76.92% beat ClearPoint Neuro's return on equity.
Delcath Systems has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Delcath Systems had 16 more articles in the media than ClearPoint Neuro. MarketBeat recorded 20 mentions for Delcath Systems and 4 mentions for ClearPoint Neuro. Delcath Systems' average media sentiment score of 1.00 beat ClearPoint Neuro's score of 0.49 indicating that ClearPoint Neuro is being referred to more favorably in the news media.
Delcath Systems presently has a consensus target price of $20.20, suggesting a potential upside of 190.23%. ClearPoint Neuro has a consensus target price of $12.00, suggesting a potential upside of 87.50%. Given ClearPoint Neuro's higher probable upside, equities research analysts plainly believe Delcath Systems is more favorable than ClearPoint Neuro.
ClearPoint Neuro has higher revenue and earnings than Delcath Systems. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
Delcath Systems received 3 more outperform votes than ClearPoint Neuro when rated by MarketBeat users. However, 86.96% of users gave ClearPoint Neuro an outperform vote while only 22.33% of users gave Delcath Systems an outperform vote.
Summary
ClearPoint Neuro beats Delcath Systems on 9 of the 17 factors compared between the two stocks.
Get ClearPoint Neuro News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ClearPoint Neuro Competitors List
Related Companies and Tools
